United Biologics, LLC v. American Academy of Allergy Asthma & Immunology

CourtDistrict Court, W.D. Texas
DecidedMay 17, 2021
Docket5:14-cv-00035
StatusUnknown

This text of United Biologics, LLC v. American Academy of Allergy Asthma & Immunology (United Biologics, LLC v. American Academy of Allergy Asthma & Immunology) is published on Counsel Stack Legal Research, covering District Court, W.D. Texas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United Biologics, LLC v. American Academy of Allergy Asthma & Immunology, (W.D. Tex. 2021).

Opinion

UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF TEXAS SAN ANTONIO DIVISION UNITED BIOLOGICS, L.L.C. and ACADEMY OF ALLERGY & ASTHMA IN PRIMARY CARE, Plaintiffs, v. Case No. 5:14-cv-35-RCL ALLERGY AND ASTHMA NETWORK/MOTHERS OF ASTHMATICS, INC. and TONYA WINDERS, Defendants.

MEMORANDUM OPINION In January 2014, the plaintiffs sued the defendants for alleged antitrust violations, tortious interference with existing and prospective business relations, and civil conspiracy. Complaint at {9 77-97, ECF No. 1. The case eventually went to trial in 2018, and the plaintiffs lost before a jury. Jury Verdict, ECF No. 563; Judgment, ECF No. 564. Shortly after, the defendants submitted their bill of costs. Bill of Costs (“BOC”), ECF No. 565. The plaintiffs then moved for a new trial or judgment notwithstanding the verdict. Mot., ECF No. 584. The Court denied those motions, and the plaintiffs appealed. Mem. Op., ECF No. 596; Order, ECF No. 597; Not. of Appeal, ECF No. 600. The Fifth Circuit affirmed and issued the mandate on August 12, 2020. ECF No. 648. Two days later, the defendants submitted an amended bill of costs to this Court. Amended BOC, ECF No. 649. The defendants seek to tax $141,395.63 of their litigation expenses as costs. Jd. The plaintiffs timely objected. Objection, ECF No. 653. Thus, the Court now assesses the defendants’ amended “proposed bill of costs . . . for final resolution.” Local Rule CV-54. Having reviewed the

parties’ briefing and supporting attachments, the Court will GRANT IN PART and DENY IN PART the defendants’ amended bill of costs. Specifically, it holds that the defendants may tax only $79,080.38 of their expenses as costs. I. BACKGROUND The Court takes the following facts from their succinct restatement by the Fifth Circuit on appeal. United Biologics, L.L.C., which does business as United Allergy, “offers an alternative way to obtain allergy treatment.” United Biologics, L.L.C. v. Allergy and Asthma Network/Mothers of Asthmatics, Inc., 819 F. App’x 204, 206 (Sth Cir. 2020). Traditionally, allergy-sufferers “seek treatment from a certified allergist[,] who administers immunotherapy.” /d. But United Allergy sought to disrupt the traditional model. It contracted “directly with primary-care physicians,” rather than certified allergists, to furnish immunotherapy services. Jd. “In exchange for a fee, United Allergy would provide technicians and assist physicians with immunotherapy equipment and supplies.” /d. In support of that business model, “United Allergy helped form and fund” co- plaintiff Academy of Allergy & Asthma in Primary Care, “a non-profit organization of physicians that ‘represent[s] the interests of . . . primary care physicians that provide allergy and asthma care to their patients.’” Jd. Defendant Tonya Winders, by contrast, was aligned with the traditional model of allergy treatment. She was “first the market development team leader at Phadia”—a company that sells equipment for traditional allergy tests—‘“and later the president and CEO” of co-defendant Mothers of Asthmatics, “a patient advocacy organization.” Jd. “While at Phadia, Winders identified United Allergy as a market obstacle to traditional allergy businesses.” Jd. So Winders began exploring how to undermine United Allergy. As Winders’s co-worker explained, they hoped to “compile a broad strategy to wipe these [companies] off the face of the earth.” Jd.

“By August 2011, Winders had formulated what she called ‘[her] plan for leading the charge to stop this market obstacle from negatively impacting [business] further.” Jd. The plan, in essence, involved Phadia directing its sales consultants to disseminate information to physicians that portrayed the “traditional” model in a positive light relative to companies like United Allergy. Phadia’s “talking points” included the ideas that (1) patients are safer when receiving traditional allergy and asthma care, (2) board-certified allergists receive extensive training to become board certified and prepared to address potential problems, and (3) the billing practices of remote allergy providers are concerning and could implicate providers if found to be illegal.” Jd. In November, the U.S. Department of Health and Human Services’s Office of the Inspector General (OIG) lent some credence to Phadia’s claims. /d. It “issued an advisory opinion regarding a business model similar to United Allergy’s and concluded that it ‘could potentially generate prohibited remuneration under the anti-kickback statute.’” Jd. (citing U.S. Dep’t of Health & Hum. Servs., Re: OIG Advisory Opinion No. 11-17, at 1 (Nov. 23, 2011)). Phadia “shared the opinion internally as something that would ‘help combat . . . these companies.’” Jd. And “[iJt also shared the opinion with a company that was negotiating with United Allergy, the Hospital Corporation of America [“HCA”].” Jd. Later, a “Phadia employee” remarked that he might have “prevented a clinic from signing on with [United Allergy].” Jd. “Phadia also distributed publications authored by Mothers, and on one occasion, an insurance provider Phadia had contacted told non-certified physicians to cease remote allergy treatments. Mothers also campaigned against remote allergy practice, including by distributing articles .. . under Winders’s direction.” Jd. at 206-07. Then, “[bJeginning in 2013, United Allergy’s business declined[.]” /d. at 207. “[I]t lost insurance reimbursements and ultimately substantially diminished its business. Academy, for its part, lost many of its members.” Jd. Believing Winders, Mothers of Asthmatics, and several other

entities responsible for those losses, the plaintiffs filed suit in 2014. Jd. They eventually settled with all defendants other than Winders and Mothers of Asthmatics, who took their defenses to trial. Id. At trial, the plaintiffs proceeded to lose on every claim they brought. /d. The Court “entered a directed verdict on the issue of civil conspiracy. The jury then unanimously found that neither Mothers nor Winders individually committed tortious interference.” Jd. The Court rendered its judgment for the defendants on March 27, 2018. Judgment, ECF No. 564. It also denied the plaintiffs’ motions for a new trial or judgment notwithstanding the verdict. Order, ECF No. 597. The plaintiffs appealed the jury verdict and the resultant judgment for the defendants, along with the Court’s denials of their motions for a new trial or judgment notwithstanding the verdict, in March 2019. Not. of Appeal, Min. Entry 3/25/2019. On appeal, the Fifth Circuit affirmed this Court’s judgment. United Biologics, L.L.C., 819 F. App’x at 206. Because the plaintiffs did not appeal their loss on the antitrust claims, the Circuit focused on the issues of civil conspiracy and tortious interference. Though it held this Court’s entry of a directed verdict on the issue of civil conspiracy technically improper,! id. at 208, it noted that the plaintiffs’ claims still failed as a matter of law. Jd. at 209-10. Texas’s civil conspiracy tort requires proof of another, “underlying tort” that formed the basis of the conspiracy. Id. at 209. Yet the plaintiffs presented no “evidence that could support a finding in their favor on each element of either alleged underlying tort: (a) tortious interference with existing contracts, or (b) tortious interference with prospective business relations.” Jd. at 210.

! This Court entered a directed verdict for the defendants on the civil conspiracy issue after agreeing with them that civil conspiracy was legally impossible because Phadia, which allegedly committed the underlying torts, had already settled. 3/20/18 Tr. at 35:1-3, ECF No. 590. The Fifth Circuit disagreed with that conclusion but affirmed on the alternative ground that while Texas law still allowed the plaintiffs to make a civil conspiracy claim despite Phadia’s settlement, the plaintiffs had presented legally insufficient evidence of any underlying tort.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Louisiana Power & Light Co. v. Kellstrom
50 F.3d 319 (Fifth Circuit, 1995)
Pacheco v. Mineta
448 F.3d 783 (Fifth Circuit, 2006)
West Virginia University Hospitals, Inc. v. Casey
499 U.S. 83 (Supreme Court, 1991)
Kansas v. Colorado
556 U.S. 98 (Supreme Court, 2009)
Workman v. Mingo County Board of Education
419 F. App'x 348 (Fourth Circuit, 2011)
In Re Ricoh Co., Ltd. Patent Litigation
661 F.3d 1361 (Federal Circuit, 2011)
Taniguchi v. Kan Pacific Saipan, Ltd.
132 S. Ct. 1997 (Supreme Court, 2012)
Shreve v. United States
103 F.2d 796 (Ninth Circuit, 1939)
Baisden v. I'M READY PRODUCTIONS, INC.
793 F. Supp. 2d 970 (S.D. Texas, 2011)
Ernest Gibson v. American Cyanamid Company
760 F.3d 600 (Seventh Circuit, 2014)

Cite This Page — Counsel Stack

Bluebook (online)
United Biologics, LLC v. American Academy of Allergy Asthma & Immunology, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-biologics-llc-v-american-academy-of-allergy-asthma-immunology-txwd-2021.